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The World Health Organization (WHO) estimates that >50% of 
all medicines are inappropriately prescribed, dispensed or sold. 
Together with the global estimate that half of all patients do not use 
medicines appropriately, this constitutes a significant wastage of 
limited resources.[1] Irrational medicine use is a significant problem 
in developing countries, as such countries have poorly functioning 
health systems where mechanisms for routine monitoring of 
medication use are underdeveloped or entirely absent.[2] 
Medicine-use evaluation (MUE) is an effective tool that may be 
used to overcome irrational medicine use. It is a type of quality-
improvement strategy that employs an ongoing, systematic, criteria-
based approach to evaluate medicine use and ensure optimal patient 
outcomes.[3,4] MUEs follow a quality-improvement approach, where 
the primary function is to analyse practice performance and highlight 
areas for improvement.[5]
The main objectives of MUEs are to improve and standardise 
medication-use processes, promote cost-effective therapy and ensure 
patient safety. Various categories of medicines and/or medicine-
related events can serve as indicators of possible concerns in the 
medication-use process, and are therefore employed to identify target 
areas for MUEs.[3] These include medicines that are associated with 
inappropriate use, high-cost medicines, medicines or medication-use 
processes where suboptimal administration is expected to negatively 
impact patient outcomes, medicines that are potentially toxic at 
standard doses and medicines that are being considered for retention 
in, as an addition to or for deletion from a formulary.[3,4,6]
Doxazosin is a selective α1-adrenergic receptor antagonist, which 
induces vasodilation and reduces peripheral vascular resistance. It 
is typically used as part of multidrug regimens in the treatment of 
hypertension – more specifically resistant hypertension. It is also 
used for the treatment of lower-urinary tract symptoms related to 
benign prostatic hyperplasia.[7,8] Doxazosin is not recommended as 
a first-line antihypertensive agent, which is primarily related to the 
findings of the Antihypertensive  and Lipid-Lowering Treatment 
to Prevent Heart Attack Trial (ALLHAT). ALLHAT revealed that 
doxazosin had an inferior antihypertensive effect compared with 
other agents, which led to various guidelines recommending against 
doxazosin monotherapy in hypertension. The trial also showed that 
doxazosin was associated with a higher risk of stroke and heart failure 
than chlorthalidone in high-risk hypertensive patients.[9,10]
Doxazosin use as a fourth-line agent in resistant hypertension, where 
≥4 antihypertensive agents are required to achieve normotension, 
is decreasing.[8,11] This has occurred primarily in response to the 
findings of the PATHWAY-2 (spironolactone v. placebo, bisoprolol, 
and doxazosin to determine the optimal treatment for drug-resistant 
hypertension) randomised controlled trial, which demonstrated the 
superior efficacy of spironolactone as a fourth-line agent in resistant 
hypertension when compared with doxazosin and bisoprolol.[12] This 
finding has been supported by larger meta-analyses and systematic 
reviews.[11,13] 
The use of doxazosin is restricted in the Western Cape Province’s 
public healthcare sector, where it is only recommended for treating 
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phaeochromocytoma[14,15] and as a fourth-line antihypertensive agent.[16] 
In accordance with Western Cape Government Health (WCGH) 
policy, doxazosin initiation was restricted to specialist physicians 
and paediatricians. In 2018, an application was submitted to the 
WCGH Provincial Pharmacy and Therapeutics Committee (PPTC) 
requesting that the restriction be reduced to allow family physicians 
to initiate doxazosin at a primary healthcare (PHC) level. For this 
request to be considered, the PPTC needed to ascertain whether 
doxazosin was being used appropriately, as its usage had increased 
with time. Therefore, the PPTC endorsed a recommendation to 
investigate doxazosin (standard formulation) use in the Western 
Cape. This investigation was to be conducted in all provincial public 
sector healthcare facilities through the use of an MUE. Data from 
the WCGH Medical Depot (CMD) revealed that doxazosin was 
widely used in PHC facilities, where 247 918 packs of 4 mg tablets 
(30s) were issued from 1 August 2017 to 31 July 2018. The total 
cost of these purchases was calculated at ZAR6 744 995. Therefore, 
concerns regarding inappropriate prescribing, together with high use 
(in relation to doxazosin’s restricted use) and high cost, had been 
recognised.
Methods
The design comprised a retrospective, multicentre prescription 
review. This review was intended to inform on a potential adoption 
of an MUE at all provincial public sector facilities. 
The study population included urban and rural adult outpatients 
(≥18 years of age) who were prescribed doxazosin, which was 
dispensed by the WCGH Chronic Dispensing Unit (CDU) from 
1 August to 31 December 2018. Patients receiving medicines from the 
CDU are stabilised on maintenance doses of all of their treatments, 
including doxazosin. Therefore, patients who had not been stabilised 
on maintenance doses of doxazosin were excluded from the study. 
The estimated prevalence of resistant hypertension in South Africa 
(SA) is 12.1%.[17] Based on this prevalence, a sample of 163 prescrip-
tions was required. 
Information was collected retrospectively from electronic CDU 
prescriptions. Electronic copies of prescriptions were randomly 
selected from the CDU database using random systematic selection. 
This was conducted through the randomisation of a list of patient 
folder numbers, followed by patient selection at fixed, periodic 
intervals. The corresponding electronic prescriptions were then 
retrieved from the CDU database. Data from electronic prescriptions 
were recorded with the use of a predesigned and piloted data 
collection tool. Information collected was captured onto a predesigned 
Microsoft Office Excel (Microsoft, USA) spreadsheet, from where 
analyses were performed. 
MUE criteria were established in accordance with recommendations 
provided by the SA Standard Treatment Guidelines (STG) and 
Essential Medicines List (EML) for PHC level (2014),[14] adult hospital 
level (2015),[15] as well as the WCGH Provincial Code List (2018).[16] 
The Code List, which functions as a formulary, was released by the 
WCGH to provide guidance on the use of doxazosin 1 mg tablets 
in the Western Cape. It also provides information on prescribing 
restrictions related to the use of 4 mg doxazosin tablets as a 
fourth-line antihypertensive agent – only specialist physicians and 
paediatricians are allowed to prescribe it. Table 1 provides approved 
indications and dosages for doxazosin in accordance with the 
aforementioned guidelines and Code List. 
Target thresholds for adherence to guideline recommendations for 
indication and dosage were set at 95%. As doxazosin was prescribed 
predominantly at PHC level, 95% of all identified prescriptions 
should have adhered to the requirements set out by the relevant 
guidelines. Therefore, a deviation of 5% from these requirements 
was set for outliers that were deemed appropriate owing to patient-
specific factors, such as medicine allergies. 
Ethical approval
Approval to conduct the study was granted by the WCGH PPTC, 
as well as the University of the Western Cape Biomedical Research 
Ethics Committee (ref. no. BM18/4/5). 
Results 
The sample consisted of 171 prescriptions, which were randomly 
selected from 8 080 prescriptions that were available on the WCGH 
CDU database. There were approximately twice as many females as 
males (68% v. 32%). The mean age of patients comprising the total 
sample was 61 years – gender and age are given in Table 2. 
The type of healthcare facility where doxazosin was prescribed 
was also investigated. Community health centres (CHCs), clinics and 
community day centres (CDCs) comprised 36%, 37% and 21% of 
the total sample, respectively. These equate to a total contribution of 
94% to the total sample, while the remaining 6% consisted of district 
hospitals. 
The proportion of the total sample by district/substructure was 
also investigated. Facilities from rural areas comprised 58% of the 
total sample, while the remaining 42% consisted of facilities located 
Table 1. Criteria for evaluation 
South African STGs and EML for PHC level[14] and adult hospital level[15] 
Indication Phaeochromocytoma
Total daily dosage, mg 1 - 16 
WCGH Provincial Code List[16] 
Indication Hypertension (fourth-line therapy)
Total daily dosage, mg 1 - 8 
STG = Standard Treatment Guidelines; EML = Essential Medicines List; PHC = primary healthcare; WCGH = Western Cape Government Health.
Table 2. Demographics of patient sample (N=171)
Gender Patients, n Sample, % Mean age, years (SD) Minimum age, years Maximum age, years
Female 116 68 60 (10.6) 37 89
Male 55 32 61 (10.0) 43 80
Total 171 100 61 (10.4) 37 89
SD = standard deviation.
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in the Cape Metropole. The Cape Winelands, Eden and South-
Western districts contributed the most to the proportion of the total 
sample – 23%, 16% and 15%, respectively. The Eastern/Khayelitsha, 
Northern/Tygerberg, Klipfontein/Mitchell’s Plain and Central Karoo 
districts comprised 13%, 10%, 4% and 1% of the total sample, 
respectively. Both the Overberg and West Coast districts comprised 
9% of the total sample. 
A total of 179 indications were observed from the 171 doxazosin 
prescriptions included in the sample. Seven patients used doxazosin 
for both hypertension and benign prostatic hyperplasia, while 1 patient 
used doxazosin for both hypertension and unconfirmed urinary 
incontinence. The predominant indication for doxazosin was as a 
fourth-line agent for the treatment of hypertension (i.e. doxazosin was 
prescribed concurrently with a minimum of 3 other antihypertensive 
medications as per the Code List).[16] The remaining indications for 
doxazosin contributed to 18% of the proportion of the total sample. 
These indications included hypertension, where doxazosin was 
prescribed as a first-, second- or third-line agent, and constituted 
13% of the total sample. Doxazosin indications for benign prostatic 
hyperplasia were also evident from the findings and made up 4% 
of the sample. No cases of phaeochromocytoma were observed in 
this sample. Fig. 1 displays the proportion of the various indications 
identified for doxazosin use.
The most predominantly identified total daily dose for doxazosin 
was 4 mg, which constituted 62% of the total sample. This was 
followed by 8 mg, which constituted 36% of the total sample, while 
2 mg constituted only 2% of the total sample. No total daily doses of 
>16 mg, 16 mg or 1 mg of doxazosin were observed. Fig. 2 presents the 
proportions of total daily doses of doxazosin identified from the sample.
A total of 579 antihypertensive agents were used in conjunction 
with doxazosin, which equates to an average of 3 additional anti-
hypertensive agents (Table 3). The most frequently used additional 
antihypertensive agent was amlodipine, which contributed 25% to 
the total usage. This was followed by enalapril and atenolol, which 
each made up 20% of the proportion of the total sample, respectively. 
Discussion
As the mean age of patients in the sample was 61 years, it can be 
construed that these patients were predominantly elderly. This 
finding was anticipated, as the risk of developing hypertension 
is directly correlated with increasing age.[18] As the prevalence of 
resistant hypertension is more frequently observed in persons aged 
≥60 years,[19] the age statistic of our sample is comparable. As the 
sample consisted primarily of female patients, a correlation between 
gender and potentially resistant hypertension was not ascertainable. 
The finding that PHC facilities, including CHCs, CDCs and 
clinics, comprised 94% of the total sample, was anticipated. This 
distribution was predicted, as prescriptions were identified from the 
Western Cape’s CDU database, which consists of prescriptions from 
patients who are stable while taking their chronic medications and 
are typically down-referred to PHC facilities. 
The finding that rural districts consisted of a larger proportion 
of the total sample (58%), was unexpected. However, doxazosin 
consumption data from January to March 2018 showed that 10 139 packs 
of 4 mg doxazosin tablets (30s) were used by the top 10 consuming 
facilities in the Western Cape. Of the 10  139 packs issued, rural 
facilities used 7 230 packs, while the remaining 2 909 packs were 
used by Cape Metropole facilities. Furthermore, during this period, 
6 of these top 10 consuming facilities were rural facilities. Therefore, 
it can be inferred that the finding of this MUE, where rural facilities 
were the highest consumers of doxazosin, was appropriate. 
Doxazosin was administered as a fourth-line agent for the 
treatment of hypertension, which was the most predominant 
indication identified – an approved indication as per the relevant 
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Fig. 1. Proportion of total sample by indication (N=179). 
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Fig. 2. Proportion of total daily doses of doxazosin prescribed. 
Table 3. Concurrent antihypertensive agents used in the sample 
(N=579)
Antihypertensive agent 
prescribed n (%)
Hydrochlorothiazide 95 (16)
Enalapril 116 (20)
Amlodipine 142 (25)
Losartan 22 (4)
Furosemide 60 (10)
Atenolol 114 (20)
Spironolactone 24 (4)
Carvedilol 6 (1)
Total 579 (100)
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circular.[16] The lack of doxazosin use in phaeochromocytoma, which 
was the only STG- and EML-approved indication for doxazosin, 
can be attributed to the low estimated prevalence of the disease 
(0.5% among those tested).[20] Doxazosin’s relatively low usage as 
a first-, second- or third-line antihypertensive agent indicated 
that prescribers predominantly followed the recommendations of 
the relevant guidelines and circular; however, doxazosin in these 
scenarios is unusual in the public sector and would require further 
investigation. These cases can potentially be attributed to patients 
who were intolerant to other antihypertensive agents, who were 
allergic to the other agents or who did not respond well to the use 
of other agents. Moreover, the identified low use of doxazosin in 
benign prostatic hyperplasia can be based on similar factors relative 
to its use. 
The recommended total daily dosing range for doxazosin as per 
the relevant circular is 1 - 8 mg.[16] As the 4 mg total daily dose was 
mostly identified in this study, it can be construed that prescribers 
followed the set recommendations rigorously. This was followed 
by the 8 mg total daily dose. The recommended initiation dose of 
doxazosin in hypertension is 1 mg daily.[21] Therefore, the findings 
of this study indicate that the majority in the sample were stable 
chronic hypertensive patients. This result was anticipated, as the 
prescriptions were collected from the CDU, where patients who 
are classified as stable while receiving their chronic regimens have 
such medications prepacked. Prescriptions submitted to the CDU 
should be for patients who have been stabilised on a maintenance 
dose before referral. The study showed that most patients received 
4 mg daily (62%), followed by 8 mg daily (36%), which is in line with 
recommended maintenance doses. 
The average number of concurrently prescribed antihypertensive 
agents was 3 per patient, which indicates that doxazosin was 
used predominantly in combination with at least 3 other agents. 
Doxazosin was therefore most likely used as a fourth-line agent 
for treating hypertension. However, as amlodipine (25%), enalapril 
(20%) and atenolol (20%) were the most co-prescribed agents, it can 
be inferred that adherence to the STG and EML stepwise approach 
to treating hypertension was lacking. In terms of medicine therapy, 
this stepwise approach recommends the use of hydrochlorothiazide 
initially, followed by the addition of either an angiotensin-converting 
enzyme (ACE) inhibitor or a long-acting calcium channel blocker.[14,15] 
Therefore, a more appropriate finding would have been greater 
use of hydrochlorothiazide, which comprised only 16% of the 
total sample. The prescribing of doxazosin fell 13% short of the 
approved indication threshold, which was set at 95%. Although this 
deficit may be interpreted as being marginal, recommendations to 
enhance practice performance should be encouraged. Therefore, several 
recommen dations have been outlined. 
Pharmacy staff should be encouraged to be vigilant of all 
prescriptions for doxazosin and should note the indications listed. 
If any unapproved indications are present, they should query the 
indication with the relevant prescriber, who should be a specialist 
physician or a paediatrician. To ensure the support of pharmacy staff 
in this regard, a circular describing the need to review all indications 
listed for doxazosin on prescriptions can be distributed. 
Healthcare facilities can implement a monthly or bi-monthly 
monitoring strategy for doxazosin use. This strategy should entail 
the evaluation of issues and/or purchases of doxazosin to assess 
prescribing trends and increased consumption. This strategy has 
the potential to inform future MUEs and target areas for practice 
improvement. 
The WCGH PPTC should consider endorsing a follow-up province-
wide MUE for doxazosin. This should be implemented in every public 
sector healthcare facility, where a retrospective folder review can be 
conducted. It will allow facility staff to gauge their adherence to the 
set recommendations and encourage them to improve prescribing 
behaviours with regard to doxazosin usage. 
As the threshold deficit was relatively low, the PPTC and other 
stakeholders should consider reducing prescribing restrictions 
on doxazosin use. This would allow more patients to benefit 
from the medication and encourage prescribers to adhere to set 
recommendations. However, further strategies to improve doxazosin 
monitoring should be implemented concurrently with a reduction in 
restrictions.
Conclusions
MUEs are an unexploited resource for medication-use monitoring 
and practice improvement in developing countries. They offer 
a unique, cost-effective system to improve medicine use in any 
setting. As this MUE revealed a relatively minor concern with 
doxazosin prescribing, MUEs may also inform formulary changes 
and influence policy. This was demonstrated by the finding of this 
MUE, where inappropriate prescribing of doxazosin was ascertained 
to be only 13%. In light of this, the WCGH PPTC amended the policy 
regarding doxazosin prescription restrictions, where it would permit 
family physicians to prescribe the medication. Follow-up MUEs 
and other strategies to improve medicine use should be conducted 
after an initial MUE to ensure continuous practice evaluation 
and improvement. MUE success is founded on multidisciplinary 
participation and organisation, which must oversee contin uous cycles 
of practice evaluation, intervention and change. Opportunities for the 
use of MUEs should be systematically identified and form a routine 
part of clinical practice moving forward. 
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